Developmental Aspects and Pathological Findings in Spinal Muscular Atrophy

Spinal Muscular Atrophy: Disease Mechanisms and Therapy

Volumn , Issue , 2017, Pages 21-42

  Perez Garcia M J ^a   Kong, L ^b   Sumner, C J ^b   Tizzano, E F ^a,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Axon; Human development; Motor neuron; Muscle; Myofibers; Neuromuscular junction; Neuropathology; Programmed cell death; Spinal muscular atrophy

Indexed keywords

EID: 85027268364     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803685-3.00002-1     Document Type: Chapter

References (129)

1. Werdnig G. Zwei frühinfantile hereditäre Fälle von pro-gressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Arch Psychiatr Nervenkr 1891, 22:437-481.
2. Hoffmann J. Üeber chronische spinale muskelatrophie im kindesalter, auf familiärer basis. Dtsch Z Nervenheilkd 1893, 3(6):427-470.
3. Stiles J., Jernigan T.L. The basics of brain development. Neuropsychol Rev 2010, 20(4):327-348.
4. Takahashi Y., Osumi N., Patel N.H. Body patterning. Proc Natl Acad Sci USA 2001, 98(22):12338-12339.
5. Loebel D.A., et al. Lineage choice and differentiation in mouse embryos and embryonic stem cells. Dev Biol 2003, 264(1):1-14.
6. Gammill L.S., Bronner-Fraser M. Neural crest specification: migrating into genomics. Nat Rev Neurosci 2003, 4(10):795-805.
7. Burlet P., et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet 1998, 7(12):1927-1933.
8. Cajal S.R. Degeneration and Regeneration in the Nervous System 1928, 396-410. Oxford University Press.
9. Rousso D.L., et al. Coordinated actions of the forkhead protein Foxp1 and Hox proteins in the columnar organization of spinal motor neurons. Neuron 2008, 59(2):226-240.
10. Davis-Dusenbery B.N., et al. How to make spinal motor neurons. Development 2014, 141(3):491-501.
11. Philippidou P., Dasen J.S. Hox genes: choreographers in neural development, architects of circuit organization. Neuron 2013, 80(1):12-34.
12. Richardson W.D., Kessaris N., Pringle N. Oligodendrocyte wars. Nat Rev Neurosci 2006, 7(1):11-18.
13. Marmigere F., Ernfors P. Specification and connectivity of neuronal subtypes in the sensory lineage. Nat Rev Neurosci 2007, 8(2):114-127.
14. Oppenheim R.W. Cell death during development of the nervous system. Annu Rev Neurosci 1991, 14:453-501.
15. Wu D., Hersh L.B. Choline acetyltransferase: celebrating its fiftieth year. J Neurochem 1994, 62(5):1653-1663.
16. Schiaffino S., et al. Developmental myosins: expression patterns and functional significance. Skeletal Muscle 2015, 5:22.
17. Kuang S., Gillespie M.A., Rudnicki M.A. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2008, 2(1):22-31.
18. Wirsen C., Larsson K.S. Histochemical differentiation of skeletal muscle in foetal and newborn mice. J Embryol Exp Morphol 1964, 12:759-767.
19. Hausmanowa-Petrusewicz I., et al. Is Kugelberg-Welander spinal muscular atrophy a fetal defect?. Muscle Nerve 1980, 3(5):389-402.
20. Engel A.G. The neuromuscular junction. Handb Clin Neurol 2008, 91:103-148.
21. van Ooyen A., Willshaw D.J. Poly- and mononeuronal innervation in a model for the development of neuromuscular connections. J Theor Biol 1999, 196(4):495-511.
22. Kurjak A., et al. The assessment of fetal neurobehavior by three-dimensional and four-dimensional ultrasound. J Matern Fetal Neonatal Med 2008, 21(10):675-684.
23. Lefebvre S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80(1):155-165.
24. Burglen L., et al. Survival motor neuron gene deletion in the arthrogryposis multiplex congenita-spinal muscular atrophy association. J Clin Invest 1996, 98(5):1130-1132.
25. Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum Mol Genet 1997, 6:1961-1971.
26. Tizzano E.F., Cabot C., Baiget M. Cell-specific survival motor neuron gene expression during human development of the central nervous system: implications for the pathogenesis of spinal muscular atrophy. Am J Pathol 1998, 153(2):355-361.
27. Webster M.T., et al. Glutamate toxicity in rat cultured neurones: effects on amyloid precursor-like protein 2. Neurosci Lett 1999, 276(2):107-110.
28. Boza-Moran M.G., et al. Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons. Sci Rep 2015, 5:11696.
29. Soler-Botija C., et al. Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function?. J Neuropathol Exp Neurol 2005, 64(3):215-223.
30. Ruggiu M., et al. A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol 2012, 32(1):126-138.
31. Soler-Botija C., et al. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain 2002, 125(Pt. 7):1624-1634.
32. Kerr D.A., et al. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci USA 2000, 97(24):13312-13317.
33. Fidzianska A., Rafalowska J. Motoneuron death in normal and spinal muscular atrophy-affected human fetuses. Acta Neuropathol 2002, 104(4):363-368.
34. Cifuentes-Diaz C., et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet 2002, 11(12):1439-1447.
35. Soler-Botija C., et al. Downregulation of Bcl-2 proteins in type I spinal muscular atrophy motor neurons during fetal development. J Neuropathol Exp Neurol 2003, 62(4):420-426.
36. Simic G., et al. Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 2000, 59(5):398-407.
37. -/- mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9(3):333-339.
38. Mentis G.Z., et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 2011, 69(3):453-467.
39. Soler C, Cuscó I, López E, et al. Choline acetyltransferase expression does not identify early pathogenic events in fetal SMA spinal cord. Neuromuscul Disord 2005, 15:253-258.
40. Simic G., et al. Abnormal motoneuron migration, differentiation, and axon outgrowth in spinal muscular atrophy. Acta Neuropathol 2008, 115(3):313-326.
41. Chou S.M., Wang H.S. Aberrant glycosylation/phosphorylation in chromatolytic motoneurons of Werdnig-Hoffmann disease. J Neurol Sci 1997, 152(2):198-209.
42. Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol 2008, 116(3):223-234.
43. Korinthenberg R., et al. Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. Ann Neurol 1997, 42(3):364-368.
44. Robertson W.C., Kawamura Y., Dyck P.J. Morphometric study of motoneurons in congenital nemaline myopathy and Werdnig-Hoffmann disease. Neurology 1978, 28(10):1057-1061.
45. Marshall A., Duchen L.W. Sensory system involvement in infantile spinal muscular atrophy. J Neurol Sci 1975, 26(3):349-359.
46. Ito Y., et al. New insights into the pathogenesis of spinal muscular atrophy. Brain Dev 2011, 33(4):321-331.
47. Araki S., et al. Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol 2003, 106(5):441-448.
48. Hayashi M. A 5-year-old girl with muscle atrophy lacking motor developments after spontaneous sitting. Neuropathology 2004, 24(4):347-349.
49. Kuzuhara S., Chou S.M. Preservation of the phrenic motoneurons in Werdnig-Hoffmann disease. Ann Neurol 1981, 9(5):506-510.
50. Greenfield J.G., Stern R.O. The anatomical identity of the Werdnig-Hoffmann and Oppenheim forms of infantile muscular atrophy. Brain 1927, 50(3-4):652-686.
51. Dachs E., et al. Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal muscular atrophy. J Neuropathol Exp Neurol 2011, 70(6):444-461.
52. Fidzianska A., Rafalowska J., Glinka Z. Ultrastructural study of motoneurons in Werdnig-Hoffmann disease. Clin Neuropathol 1984, 3(6):260-265.
53. Harding B.N., et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol 2015, 74(1):15-24.
54. Burlet P., et al. Large scale deletions of the 5q13 region are specific to Werdnig-Hoffmann disease. J Med Genet 1996, 33(4):281-283.
55. Roy N., et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80(1):167-178.
56. Lippa C.F., Smith T.W. Chromatolytic neurons in Werdnig-Hoffmann disease contain phosphorylated neurofilaments. Acta Neuropathol 1988, 77(1):91-94.
57. Kato S., Hirano A. Ubiquitin and phosphorylated neurofilament epitopes in ballooned neurons of the extraocular muscle nuclei in a case of Werdnig-Hoffmann disease. Acta Neuropathol 1990, 80(3):334-337.
58. Murayama S., Bouldin T.W., Suzuki K. Immunocytochemical and ultrastructural studies of Werdnig-Hoffmann disease. Acta Neuropathol 1991, 81(4):408-417.
59. Chou S.M., Fakadej A.V. Ultrastructure of chromatolytic motoneurons and anterior spinal roots in a case of Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 1971, 30(3):368-379.
60. Ikemoto A., et al. Synaptophysin expression in the anterior horn of Werdnig-Hoffmann disease. J Neurol Sci 1996, 136(1-2):94-100.
61. Yamanouchi Y., Yamanouchi H., Becker L.E. Synaptic alterations of anterior horn cells in Werdnig-Hoffmann disease. Pediatr Neurol 1996, 15(1):32-35.
62. Graeber M.B., Streit W.J. Microglia: immune network in the CNS. Brain Pathol 1990, 1(1):2-5.
63. Graeber M.B., Bise K., Mehraein P. Synaptic stripping in the human facial nucleus. Acta Neuropathol 1993, 86(2):179-181.
64. Gogliotti R.G., et al. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci 2012, 32(11):3818-3829.
65. Ling K.K., et al. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS One 2010, 5(11):e15457.
66. Vrbova G., Lowrie M.B. The role of nerve-muscle interactions in the pathogenesis of spinal muscular atrophy. Neuromuscular Diseases: From Basic Mechanisms to Clinical Management 1988, 33-42. Fisher Publishing Group.
67. Kuru S., et al. An autopsy case of spinal muscular atrophy type III (Kugelberg-Welander disease. Neuropathology 2009, 29(1):63-67.
68. Rindt H., et al. Astrocytes influence the severity of spinal muscular atrophy. Hum Mol Genet 2015, 24(14):4094-4102.
69. Papadimitriou D., et al. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010, 37(3):493-502.
70. Chou S.M., Nonaka I. Werdnig-Hoffmann disease: proposal of a pathogenetic mechanism. Acta Neuropathol 1978, 41(1):45-54.
71. Norman R.M. Cerebellar hypoplasia in Werdnig-Hoffmann disease. Arch Dis Child 1961, 36:96-101.
72. Norman R.M., Kay J.M. Cerebello-thalamo-spinal degeneration in infancy: an unusual variant of Werdnig-Hoffmann disease. Arch Dis Child 1965, 40:302-308.
73. Shishikura K., et al. A neuropathologic study of Werdnig-Hoffmann disease with special reference to the thalamus and posterior roots. Acta Neuropathol 1983, 60(1-2):99-106.
74. Nieves G.M., Castello J.C. Pathological findings in Werdnig-Hoffmann's disease with special remarks on diencephalic lesions. Eur Neurol 1970, 3(4):231-240.
75. Briese M., et al. SMN, the product of the spinal muscular atrophy-determining gene, is expressed widely but selectively in the developing human forebrain. J Comp Neurol 2006, 497(5):808-816.
76. Ghatak N.R. Spinal roots in Werdnig-Hoffmann disease. Acta Neuropathol 1978, 41(1):1-7.
77. Carpenter S., et al. Pathological involvement of primary sensory neurons in Werdnig-Hoffmann disease. Acta Neuropathol 1978, 42(2):91-97.
78. Probst A., et al. Sensory ganglioneuropathy in infantile spinal muscular atrophy. Light and electronmicroscopic findings in two cases. Neuropediatrics 1981, 12(3):215-231.
79. Chien Y.Y., Nonaka I. Peripheral nerve involvement in Werdnig-Hoffmann disease. Brain Dev 1989, 11(4):221-229.
80. Szliwowski H.B., Drochmans P. Ultrastructural aspects of muscle and nerve in Werdnig-Hoffmann disease. Acta Neuropathol 1975, 31(4):281-296.
81. Fidzianska A. Ultrastructural changes in muscle in spinal muscular atrophy. Werding-Hoffmann's disease. Acta Neuropathol 1974, 27(3):247-256.
82. Fidzianska A. Human ontogenesis. II. Development of the human neuromuscular junction. J Neuropathol Exp Neurol 1980, 39(5):606-615.
83. Fidzianska A., Goebel H.H., Warlo I. Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism. Brain 1990, 113(Pt. 2):433-445.
84. Deleted in review.
85. Woolf A.L. Muscle biopsy in the diagnosis of the "Floppy Baby": infantile hypotonia. Dev Med Child Neurol 2008, 2(1):19-27.
86. Hunter G., et al. SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Hum Mol Genet 2014, 23(9):2235-2250.
87. Lee Y.I., et al. Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol 2011, 356(2):432-444.
88. Ghatak N.R. Glial bundles in spinal nerve roots: a form of isomorphic gliosis at the junction of the central and peripheral nervous system. Neuropathol Appl Neurobiol 1983, 9(5):391-401.
89. Ghatak N.R., et al. Remyelination in multiple sclerosis with peripheral type myelin. Arch Neurol 1973, 29(4):262-267.
90. Iwata M., Hirano A. "Glial bundles" in the spinal cord late after paralytic anterior poliomyelitis. Ann Neurol 1978, 4(6):562-563.
91. Brock T.O., McIlwain D.L. Astrocytic proteins in the dorsal and ventral roots in amyotrophic lateral sclerosis and Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 1984, 43(6):609-619.
92. Martinez-Hernandez R., et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol 2009, 68(5):474-481.
93. Martinez-Hernandez R., et al. Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy. J Neuropathol Exp Neurol 2014, 73(6):559-567.
94. Fitzsimons R.B., Hoh J.F. Embryonic and foetal myosins in human skeletal muscle. The presence of foetal myosins in duchenne muscular dystrophy and infantile spinal muscular atrophy. J Neurol Sci 1981, 52(2-3):367-384.
95. Sarnat H.B. Myotubular myopathy: arrest of morphogenesis of myofibres associated with persistence of fetal vimentin and desmin. Four cases compared with fetal and neonatal muscle. Can J Neurol Sci 1990, 17(2):109-123.
96. Nadeau A., et al. A newborn with spinal muscular atrophy type 0 presenting with a clinicopathological picture suggestive of myotubular myopathy. J Child Neurol 2007, 22(11):1301-1304.
97. Van Muijen G.N., Ruiter D.J., Warnaar S.O. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 1987, 57(4):359-369.
98. Biral D., et al. Myosin heavy chain composition of muscle fibers in spinal muscular atrophy. Muscle Nerve 1989, 12(1):43-51.
99. Sarnat H.B. Vimentin and desmin in maturing skeletal muscle and developmental myopathies. Neurology 1992, 42(8):1616-1624.
100. Ripolone M., et al. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol 2015, 72(6):666-675.
101. Walsh F.S., Moore S.E. Expression of muscle cell surface antigen 5.1H11 in infantile or juvenile spinal muscular atrophy. Neurology 1986, 36(8):1140-1142.
102. Arnold A.S., et al. Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Lab Invest 2004, 84(10):1271-1278.
103. Dubowitz V. Muscle Biopsy: A Practical Approach. Chapter 9 Neurogenic Disorders 2013, III:275-292. Elsevier.
104. Mastaglia F.L., Walton J.N. Histological and histochemical changes in skeletal muscle from cases of chronic juvenile and early adult spinal muscular atrophy (the Kugelberg-Welander syndrome. J Neurol Sci 1971, 12(1):15-44.
105. Buchthal F., Olsen P.Z. Electromyography and muscle biopsy in infantile spinal muscular atrophy. Brain 1970, 93(1):15-30.
106. Kong L., et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 2009, 29(3):842-851.
107. Zalneraitis E.L., et al. Muscle biopsy and the clinical course of infantile spinal muscular atrophy. J Child Neurol 1991, 6(4):324-328.
108. Sandri M., et al. Dystrophin deficient myotubes undergo apoptosis in mouse primary muscle cell culture after DNA damage. Neurosci Lett 1998, 252(2):123-126.
109. Martinez-Hernandez R., et al. Synaptic defects in type I spinal muscular atrophy in human development. J Pathol 2013, 229(1):49-61.
110. Hausmanowa-Petrusewicz I., Vrbova G. Spinal muscular atrophy: a delayed development hypothesis. Neuroreport 2005, 16(7):657-661.
111. Wadman R.I., et al. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 2012, 79(20):2050-2055.
112. Kararizou E., et al. Morphological and morphometrical study of human muscle spindles in Werdnig-Hoffmann disease (infantile spinal muscular atrophy type I. Acta Histochem 2006, 108(4):265-269.
113. Cazzato G., Walton J.N. The pathology of the muscle spindle. A study of biopsy material in various muscular and neuromuscular diseases. J Neurol Sci 1968, 7(1):15-70.
114. Bobele G.B., et al. Hypertrophic intrafusal muscle fibers in infantile spinal muscular atrophy. J Child Neurol 1996, 11(3):246-248.
115. Swash M., Fox K.P. The pathology of the human muscle spindle: effect of denervation. J Neurol Sci 1974, 22(1):1-24.
116. Parra J., et al. Evaluation of fetal nuchal translucency in 98 pregnancies at risk for severe spinal muscular atrophy: possible relevance of the SMN2 copy number. J Matern Fetal Neonatal Med 2011, 25(8):1246-1249.
117. Zadeh N., Hudgins L., Norton M.E. Nuchal translucency measurement in fetuses with spinal muscular atrophy. Prenat Diagn 2011, 31(4):327-330.
118. Barone C., Bianca S. Further evidence of no association between spinal muscular atrophy and increased nuchal translucency. Fetal Diagn Ther 2013, 33(1):65-68.
119. Rudnik-Schoneborn S., et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 2008, 45(10):635-638.
120. Menke L.A., et al. Congenital heart defects in spinal muscular atrophy type I: a clinical report of two siblings and a review of the literature. Am J Med Genet A 2008, 146A(6):740-744.
121. Tizzano E. Spinal muscular atrophy during human development: where are the early pathogenic findings?. Adv Exp Med Biol 2009, 652:225-235.
122. MacLeod M.J., et al. Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol 1999, 3(2):65-72.
123. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999, 3(2):49-51.
124. Devriendt K., et al. Clinical and molecular genetic features of congenital spinal muscular atrophy. Ann Neurol 1996, 40(5):731-738.
125. Vrbova G. Can old observations explain the pathogenesis of SMA?. Neuromuscul Disord 2012, 22(5):381-383.
126. Bottai D., Adami R. Spinal muscular atrophy: new findings for an old pathology. Brain Pathol 2013, 23(6):613-622.
127. Hamilton G., Gillingwater T.H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013, 19(1):40-50.
128. Shababi M., Lorson C.L., Rudnik-Schoneborn S.S. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?. J Anat 2014, 224(1):15-28.
129. Somers E., et al. Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy. Neuromuscul Disord 2012, 22(5):435-442.